Celerion talks about research sector in South America

By Gareth Macdonald

- Last updated on GMT

US CRO Celerion gained Brazilian National Health Surveillance Agency (Agência Nacional de Vigilancia Sanitaria ANVISA) approval for its bioanalysis labs in Lincoln, Nebraska and in Belfast, Northern Ireland.

Celerion’s VP of clinical research Phil Bach spoke with Outsourcing-pharma.com at DIA 2011, explaining that demand from several pharma industry customers was the key driver for its efforts to gain Brazilian approval.

Bach said that Brazil’s drug market is going to be worth around $11bn by 2015 and added that this, coupled with the country’s economic stability and improving healthcare infrastructure, Is attractive to pharma companies.

Related news

Show more

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers